-
Taking a Break
Science & Enterprise is taking an early summer break, and we will not be publishing any editorial posts for the rest of this week.
-
Bacterial Genome Recoded to Produce Stable Protein Drugs
A biotechnology lab devised techniques for genetically engineered bacteria to produce synthetic proteins that can last longer and are more stable than current protein production methods.
-
Blood Tests Shown Able to Identify Early Lung Cancer
Results from a large-scale clinical trial show an analysis of blood samples can detect and identify the presence of characteristic DNA indicating a person may have early stages of lung cancer.
-
Infographic – Immigrants Boost High-Value U.S. Start-Ups
Based on data from 2016, about half — 44 of 87 — U.S. start-ups valued at $1 billion or more were founded by immigrants, with India providing the largest number of these entrepreneurs.
-
Stem Cell Transplants Found Safe for Spinal Cord Injuries
Results from a clinical trial testing transplants of neural stem cells for spinal cord injuries show the therapies are safe for patients, with signs of improvement in most participants 1 to 2 years after treatment.
-
Nanoscale Cell-Like Robots Shown to Clean Blood
Engineering researchers developed tiny robotic devices, powered by ultrasound and designed to look and act like blood cells, which in lab tests cleared human blood of dangerous bacteria and toxins.
-
Data Tools Designed for Genomics-Based Precision Cancer Care
A computerized system is available that analyzes the genomic composition of cancer patients and recommends personalized treatments that its designers say take into account a larger array of factors than comparable systems.
-
FDA Delays Crispr Trial for Inherited Blood Diseases
The U.S. Food and Drug Administration put a hold on beginning a clinical trial of the emerging genome editing technique known as Crispr to treat inherited blood disorders.
-
A Guide To Buying Industrial Machinery
It’s important to choose the right machinery for your needs while keeping within your budget.
-
Patent Awarded for Nasal Delivered Cancer Immunotherapy
A technology for cancer therapies that harnesses the immune system with nanoscale droplets suspended in an emulsion and delivered through the nose received a U.S. patent.